Table 1. High level of miR-4653-3p was associated with better disease-free survival in the validation cohort.
| Parameter | #Cases (events) | Unadjusted HR (95% CI)a | P | Adjusted HR (95% CI)b | P |
|---|---|---|---|---|---|
| miR-4653-3p relative expression | |||||
| High (≥ 0.43) | 33 (6) | 0.28 (0.12~0.68) | 0.005 | 0.17 (0.05~0.57) | 0.004 |
| Low (< 0.43) | 55 (29) | 1 | 1 | ||
| Age at diagnosis | 88 (35) | 0.97 (0.93~1.02) | 0.22 | 0.98 (0.91~1.05) | 0.56 |
| Clincal stage | |||||
| I | 17 (2) | 1 | |||
| II | 41 (14) | 3.54 (0.8~15.6) | 0.09 | ||
| III | 27 (18) | 9.42 (2.17~40.85) | 0.003 | ||
| Tumor size | |||||
| T ≤ 2 cm | 21 (4) | 1 | 1 | ||
| 2 cm < T ≤ 5 cm | 53 (23) | 2.69 (0.93~7.81) | 0.07 | 0.7 (0.17~2.85) | 0.62 |
| T > 5 cm | 11 (7) | 5.41 (1.57~18.62) | 0.007 | 0.69 (0.13~3.61) | 0.66 |
| Lymph node involvement | |||||
| Negative | 38 (6) | 1 | 1 | ||
| Positive | 49 (29) | 5.22 (2.16~12.61) | 0.0002 | 11.58 (2.87~46.67) | 0.001 |
| Tumor grade | |||||
| I/II | 35 (11) | 1 | |||
| III | 48 (23) | 1.75 (0.85~3.6) | 0.13 | ||
| Molecular subtype | |||||
| Luminal A | 24 (9) | 1 | |||
| Luminal B | 49 (18) | 1.07 (0.48~2.39) | 0.86 | ||
| Ki67 | |||||
| < 14% | 33 (12) | 1 | 1 | ||
| ≥ 14% | 49 (17) | 0.97 (0.46~2.03) | 0.93 | 1.67 (0.62~4.44) | 0.31 |
| HER2 | |||||
| Negative | 76 (27) | 1 | 1 | ||
| Positive | 5 (3) | 2.43 (0.73~8.03) | 0.15 | 5.77 (1.19~28.08) | 0.03 |
| Menopause when receiving tamoxifen | |||||
| Premenopause | 63 (23) | 1 | 1 | ||
| Postmenopause | 23 (10) | 1.06 (0.50~2.24) | 0.87 | 0.99 (0.28~3.47) | 0.99 |
| Adjuvant chemotherapy | |||||
| Yes | 84 (35) | 1 | 1 | ||
| No | 4 (0) | 0.04 (0~20.48) | 0.32 | 0.00 | 0.98 |
a
Univariate Cox proportional hazards regression models. Unknown data were not included in the analysis.
b
HR was adjusted by the following confounders: age at diagnosis, tumor size, lymph node involvement, Ki67 expression, HER2 status, menopause status when receiving tamoxifen and adjuvant chemotherapy.